Despite recent medical progress in supportive medical absent, DM present (n=318); (iii) RI present, DM absent (n=298); (iv) both RI and DM present (n=216) therapy, the frequency of hospital-acquired acute renal failure has increased in recent years from~5% to [14]. The frequency of RCIN, defined as an increase of serum creatinine Á0.5 mg/dl, was 8.5% for iohexol (I ) 6.4% [1, 2] . Even more distressing is the fact that mortality associated with acute renal failure has and 8.2% for diatrizoate (D) in group i, 7.2% (I ) and 11.1% (D) in group ii, 12.2% (I ) and 27.0% (D) in group remained high, i.e. on average~60% in more recent reports [1] [2] [3] [4] [5][6][7][8][9][10][11]. Radiocontrast-induced nephropathy iii, and finally 33.3% (I ) and 47.7% (D) in group iv.
Incidence of radiocontrast-induced nephropathy
56% it was irreversible [16 ] . Similarly, after coronary angiography 50% of patients with diabetic nephropathy (S-creatinine concentration 5.9 mg/dl ) developed RCIN, The proportion of hospital-acquired acute renal failure and in 21% dialysis treatment was required within 14 accounted for by RCIN has increased from 5% in 1977 days, although the median volume of nonionic contrast to 32% in 1987 [6, 13] , but exact figures are difficult to medium was only 30 ml [17] . obtain, since the definitions used by different researchers are not uniform. In the multicentre Iohexol Cooperative Study, 1196 patients were randomized to receive either Available modalities for prevention and treatment the nonionic contrast agent iohexol (I ) or the ionic agent of radiocontrast-induced nephropathy meglumine/sodium diatrizoate (D) for cardiac angiography [14] . Patients were stratified into four groups: Hydration (i) renal insufficiency (RI; serum creatinine Á1.5 mg/dl ) and diabetes mellitus (DM ) both absent (n=364); (ii) RI In 1981 Eisenberg et al. [18] studied 537 patients undergoing cerebral, abdominal or peripheral angiogCorrespondence and offprint requests to: Dr Bernhard K. Krämer, raphy with relatively large volumes of radiocontrast.
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They received 550 ml of normal saline and 250 ml of © 1999 European Renal Association-European Dialysis and Transplant Association A primer in radiocontrast-induced nephropathy 2831 heparinized saline per h during the procedure. RCIN be treated with low-osmolality contrast media to prevent one case of RCIN [26 ] . could be avoided by this hydration protocol and this was later recommended for any type of angiography [19] . Brown et al.
[20] studied retrospectively 518 Preventive haemodialysis patients with a baseline S-creatinine concentration of Removal of radiocontrast media in patients with pre->1.9 mg/dl who were undergoing cardiac angiograexisting renal failure by haemodialysis does not prevent phy. The 76 patients who developed RCIN had RCIN [28, 29] . received a larger volume of radiocontrast, had lower diastolic blood pressure before angiography and had less hydration before angiography than 82 matched Experimental strategies for prevention or controls. The frequency of RCIN was lower in studies treatment of radiocontrast-medium-induced using a hydration protocol compared with studies nephropathy without mandatory hydration [15, 21] . This evidence for the benefit from hydration before radiocontrast Promising experimental approaches for the prevention cannot be taken as rigorous scientific proof, however, or treatment of RCIN comprise administration of since this problem was never addressed in a controlled, atrial natriuretic peptide, endothelin-receptor blockers randomized trial with sufficient statistical power.
and prostaglandins [30] [31] [32] [33] . These compounds are currently being studied in phase II/III clinical trials. Diuretics There is no convincing proof for benefit from routine Atrial natriuretic peptide administration of furosemide or mannitol before or Atrial natriuretic peptide (ANP) increases GFR and during angiography [21] [22] [23] . Furosemide may even glomerular hydrostatic pressure by dilating afferent adversely affect renal functional prognosis. There is arterioles while constricting efferent arterioles [34] . some uncontrolled clinical evidence that temporary Furthermore, ANP blocks tubular reabsorption of interruption of administration of diuretics or angio-sodium, causes the redistribution of renal medullary tensin-converting enzyme (ACE) inhibitors before blood flow, reverses endothelin-induced vasoconstricradiocontrast administration may be beneficial.
tion and disrupts the tubuloglomerular feedback [34] . These properties made ANP an attractive candidate Calcium-channel blockers for prevention and treatment [32] . Subsequently, ANP was shown to prevent ischaemic and toxic acute renal Encouraging results have been reported for the prophy-failure [35] [36] [37] , as well as RCIN in rats and dogs lactic use of calcium-channel blockers, but this treat- [38, 39] . In a dog model of heart failure, induced by ment has not gained wide acceptance [24, 25] . In a rapid ventricular pacing, the prolonged, radiocontrastrandomized, double-blind trial Neumayer et al. [24] induced decrease in GFR could be blocked by ANP examined the effect of nitrendipine administered 24 h [38] . prior to administration of radiocontrast to patients with normal renal function. The authors found that Endothelin receptor blockers glomerular filtration rate (GFR) remained unchanged with pretreatment in contrast to a 26% decrease in The endothelins are a family ( ET-1, ET-2, ET-3) of GFR in the control group. These results were con-peptides which are potent vasoconstrictors, preferenfirmed by another study with a short-term follow-up tially in the renal vascular bed, causing intense constricof only 2 h [25].
tion of both vas afferens and vas efferens. They also counteract some of the actions of nitrous oxide (NO) and prostaglandins. They cause natriuresis at low doses Nonionic radiocontrast medium and sodium retention at higher doses [40, 41] . A role There has been considerable debate as to whether the of endothelins in RCIN is supported by the observation type of contrast medium, i.e. ionic vs nonionic, low-of endothelin release from endothelial cells after radioosmolar vs high osmolar, influences the frequency of contrast in vitro and in vivo [42, 43] . Blockade of RCIN. It has been suggested that low-osmolar radio-endothelin ET A ±ET B receptors prevents RCIN either contrast media cause less RCIN in patients with under-partially or completely [44] [45] [46] . lying renal failure with or without diabetes mellitus [14; reviewed in 26,27]. In a meta-analysis of 25 studies, Prostaglandins Barrett and Carlisle [26 ] found an odds ratio for RCIN (increase in S-creatinine concentration of more than The vasodilatory eicosanoids prostaglandin PGE 2 and PGI 2 (prostacyclin) counteract vasoconstrictive actions 0.5 mg/dl ) of 0.5 (CI 0.36-0.68) for patients with preexisting renal failure (S-creatinine concentration of endothelins [44, 47] . They dilate the afferent arterioles; and have cytoprotective effects on tubular epithe->120 mmol/l or creatinine clearance <70 ml/min). It was 0.75 (CI 0.52-1.1, n.s.) in patients with normal lium [44, 47, 48] . Most animal models of RCIN use blockade of cyclo-oxygenases, e.g. by indomethacin. renal function. Barrett and Carlisle estimated that eight patients with pre-existing renal failure would have to This observation illustrates the importance of an intact >1.5 mg/l, and diabetes mellitus in 50% of patients. Three doses of anaritide or placebo were administered RCIN was defined as an increase of S-creatinine concentration of intravenously for 30 min before and for 30 min after Á0.5 mg/dl or Á25% after 24 or 48 h in patients with pre-existing the angiographic procedure (for a maximum of 3 h). renal failure receiving placebo (PLA), 0.01 mg/kg/min of anaritide The frequency of RCIN in the placebo group was (ANA), 0.05 mg/kg/min of anaritide, and 0.1 mg/kg/min of anaritide.
Information on important confounding variables [mean baseline 19%, in the 0.01 mg/kg/min anaritide group 23%, in S-creatinine (Scr), % of diabetics, volume, and type of contrast the 0.05 mg/kg/min anaritide group 23% and in the medium] is also given. 0.1 mg/kg/min anaritide group 25%. No treatment benefit was found in subgroup analysis in diabetic was studied in 158 patients with renal failure undergoing coronary angiography [54] . The frequency of *Significant difference.
Study in patients with pre-existing renal failure receiving placebo RCIN was even higher in the endothelin receptor (PLA) or the nonselective endothelin receptor antagonist SB209670 antagonist than the placebo group ( Table 2) .
(SB). Information on important confounding variables (mean base-Radiocontrast dose and proportion of diabetic patients
line serum creatinine, % of diabetics, volume of contrast medium)
were comparable in both groups. All patients were is also given.
hydrated before administration of radiocontrast (1 ml/kg/h 0.45% saline for at least 8 h). A beneficial prostaglandin system for handling of contrast media effect of selective endothelin ETA receptor antagonists by the kidney [49, 50] .
on RCIN is not excluded, however, by the disappointing outcome of this first study.
Testing these strategies in clinical trials
Prostaglandin PGE 1 Atrial natriuretic peptide A pilot study comprised 117 patients with pre-existing renal failure (serum creatinine concentration The results of the trial of the Auriculin Anaritide Acute Renal Failure Study Group had been promising. >1.5 mg/dl; 52% diabetic patients). Three different doses of PGE 1 (10, 20 or 40 ng/kg/min) and placebo This was a multicentre, randomized, double-blind, placebo-controlled trial of anaritide (25-amino-acid were administered intravenously starting 1 h±30 min Patients with pre-existing renal failure received placebo (PLA), 10 ng/kg/min of prostaglandin PGE 1 , 20 ng/kg/min of prostaglandin PGE 1 , and 40 ng/kg/min of prostaglandin PGE 1 . Information on important confounding variables (mean baseline serum creatinine, volume and type of contrast medium) is also given. Germany in 1997 were 487 000 diagnostic cardiac 
